India’s health ministry bans pioglitazone, metamizole, and flupentixol-melitracenBMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f4366 (Published 05 July 2013) Cite this as: BMJ 2013;347:f4366
- Soumyadeep Bhaumik
India’s ministry of health and family welfare has banned the popular diabetes drug pioglitazone, the painkiller metamizole, and the psychiatric combination flupentixol with melitracen with immediate effect, because it said that their use was “likely to involve risk to human beings.”
The move is a response to a report from a parliamentary standing committee in April that criticised the ministry for failing to withdraw several drugs …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial